Amphastar Pharmaceuticals (AMPH)
(Delayed Data from NSDQ)
$42.04 USD
-0.18 (-0.43%)
Updated Jun 5, 2024 04:00 PM ET
After-Market: $42.03 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$42.04 USD
-0.18 (-0.43%)
Updated Jun 5, 2024 04:00 PM ET
After-Market: $42.03 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth A Momentum A VGM
Zacks News
Zacks.com featured highlights include PDD Holdings, Amphastar Pharmaceuticals and Suzano
by Zacks Equity Research
PDD Holdings, Amphastar Pharmaceuticals and Suzano are part of the Zacks Screen of the Week article.
3 Profitable Stocks Worth Investing in Using Net Income Ratio
by Tirthankar Chakraborty
PDD Holdings (PDD), Amphastar Pharmaceuticals (AMPH) and Suzano (SUZ) are some of the top picks with a high net income ratio.
Amphastar Pharmaceuticals (AMPH) Is Up 0.54% in One Week: What You Should Know
by Zacks Equity Research
Does Amphastar Pharmaceuticals (AMPH) have what it takes to be a top stock pick for momentum investors? Let's find out.
Factors That Make HCA Healthcare (HCA) a Lucrative Bet Now
by Zacks Equity Research
HCA Healthcare (HCA) remains well-poised for growth on the resumption of elective surgeries, acquisitions and strong cash-generation abilities.
3 Reasons Growth Investors Will Love Amphastar (AMPH)
by Zacks Equity Research
Amphastar (AMPH) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Are Medical Stocks Lagging Amphastar Pharmaceuticals (AMPH) This Year?
by Zacks Equity Research
Here is how Amphastar Pharmaceuticals (AMPH) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year.
4 Top-Ranked Profitable Stocks to Buy Using Net Income Ratio
by Tirthankar Chakraborty
PDD Holdings Inc. (PDD), Tecnoglass (TGLS), Amphastar Pharmaceuticals (AMPH) and Axon Enterprise (AXON) have been selected as the top picks with a high net income ratio.
Centene (CNC) Divests Apixio to Boost Its Core Business
by Zacks Equity Research
Centene (CNC) completes the sale of Apixio to New Mountain Capital in a bid to dispose of non-core assets and grow its core Managed Care business.
Centene (CNC) to Provide Managed Care for SoonerSelect Program
by Zacks Equity Research
Centene (CNC) wins managed care contract to serve people in Oklahoma through the SoonerSelect and SoonerSelect Children's Specialty Plan programs.
Here is Why Growth Investors Should Buy Amphastar (AMPH) Now
by Zacks Equity Research
Amphastar (AMPH) possesses solid growth attributes, which could help it handily outperform the market.
Is Amphastar Pharmaceuticals (AMPH) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Amphastar Pharmaceuticals (AMPH) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year.
Zacks.com featured highlights include Tecnoglass, Amphastar Pharmaceuticals, Turkcell Iletisim Hizmetleri, and Copa Holdings
by Zacks Equity Research
Tecnoglass, Amphastar Pharmaceuticals, Turkcell Iletisim Hizmetleri, and Copa Holdings are part of the Zacks Screen of the Week article.
4 Solid Profitable Stocks to Invest in Using Net Income Ratio
by Tirthankar Chakraborty
Tecnoglass (TGLS), Amphastar Pharmaceuticals (AMPH), Turkcell Iletisim Hizmetleri (TKC) and Copa Holdings (CPA) have been selected as the top picks with a high net income ratio.
Tenet Healthcare (THC) Gains 42.1% YTD: More Room to Run?
by Zacks Equity Research
Tenet Healthcare's (THC) aim to boost USPI's network through continuous buyouts is positioning the company well for growth.
Factors That Make Ensign Group (ENSG) a Lucrative Bet Now
by Zacks Equity Research
Ensign Group (ENSG) is well-poised for growth on increasing service revenues, an expanding healthcare portfolio and a strong capital position.
Here's Why You Should Hold UnitedHealth Group (UNH) Stock Now
by Zacks Equity Research
Membership growth, expanding government business and improving operating margin poise UnitedHealth Group (UNH) well for growth.
Zacks Industry Outlook Highlights Amphastar, Dr. Reddy's and Teva Pharmaceutical
by Zacks Equity Research
Amphastar, Dr. Reddy's and Teva Pharmaceutical have been highlighted in this Industry Outlook article.
Looking for a Growth Stock? 3 Reasons Why Amphastar (AMPH) is a Solid Choice
by Zacks Equity Research
Amphastar (AMPH) possesses solid growth attributes, which could help it handily outperform the market.
3 Generic Drug Stocks to Watch Amid Macro Headwinds
by Sundeep Ganoria
The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to AMPH, RDY and TEVA.
Is Amphastar Pharmaceuticals (AMPH) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Amphastar Pharmaceuticals (AMPH) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year.
Amphastar (AMPH) Is a Great Choice for 'Trend' Investors, Here's Why
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Amphastar (AMPH) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Amphastar Pharmaceuticals (AMPH) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Amphastar (AMPH) delivered earnings and revenue surprises of 37.78% and 7.30%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Bausch Health (BHC) Misses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Bausch (BHC) delivered earnings and revenue surprises of -30.67% and 0.32%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Are Medical Stocks Lagging Amphastar Pharmaceuticals (AMPH) This Year?
by Zacks Equity Research
Here is how Amphastar Pharmaceuticals (AMPH) and Addus HomeCare (ADUS) have performed compared to their sector so far this year.
Zacks.com featured highlights Amphastar, Alpha Metallurgical and Riley Exploration
by Zacks Equity Research
Amphastar, Alpha Metallurgical and Riley Exploration have been highlighted in this Screen of The Week article.